Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 by Gabitass, Rachel F. et al.
ORIGINAL ARTICLE
Elevated myeloid-derived suppressor cells in pancreatic,
esophageal and gastric cancer are an independent prognostic
factor and are associated with signiﬁcant elevation of the Th2
cytokine interleukin-13
Rachel F. Gabitass • Nicola E. Annels • Deborah D. Stocken •
Hardev A. Pandha • Gary W. Middleton
Received: 17 December 2010/Accepted: 22 April 2011/Published online: 5 June 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract We undertook a comprehensive analysis of
circulating myeloid-derived suppressor cells (MDSCs) and
T regulatory cells (Tregs) in pancreatic, esophageal and
gastric cancer patients and investigated whether MDSCs
are an independent prognostic factor for survival. We
evaluated a series of plasma cytokines and in particular re-
evaluated the Th2 cytokine interleukin-13 (IL-13).
Peripheral blood was collected from 131 cancer patients
(46 pancreatic, 60 esophageal and 25 gastric) and 54
healthy controls. PBMC were harvested with subsequent
ﬂow cytometric analysis of MDSC (HLADR
- Lin1
low/-
CD33
? CD11b
?) and Treg (CD4
? CD25
? CD127
low/-
FoxP3
?) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12 (p70), IL-13, IL-17, G-CSF, IFN-c, TNF-a and
VEGF levels were analyzed by the Bio-Plex cytokine
assay. Plasma arginase I levels were analyzed by ELISA.
MDSCs and Tregs were statistically signiﬁcantly elevated
in pancreatic, esophageal and gastric cancer compared with
controls, and MDSC numbers correlated with Treg levels.
Increasing MDSC percentage was associated with
increased risk of death, and in a multivariate analysis,
MDSC level was an independent prognostic factor for
survival. A unit increase in MDSC percentage was asso-
ciated with a 22% increased risk of death (hazard ratio
1.22, 95% conﬁdence interval 1.06–1.41). Arginase I levels
were also statistically signiﬁcantly elevated in upper gas-
trointestinal cancer patients compared with controls. There
was Th2 skewing for cytokine production in all three dis-
eases, and importantly there were signiﬁcant elevations of
the pivotal Th2 cytokine interleukin-13, an increase that
correlated with MDSC levels.
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Introduction
Many cancers are characterized by the overproduction of a
range of immunosuppressive cells and cytokines. These not
only inhibit the host’s antitumor immune response but also
thwart attempts to augment anticancer immunity through
the use of cancer vaccines. The two best-characterized
immunosuppressive cell subsets are FoxP3
? T regulatory
cells (Tregs) and myeloid-derived suppressor cells
(MDSCs). The characteristics of both of these cell types
have been the subject of comprehensive recent reviews [1,
2]. MDSCs arise from myeloid progenitor cells that have
failed to terminally differentiate into mature granulocytes
and macrophages (HLADR
- Lin1
low/-). Granulocytic
MDSCs express CD33, CD11b, IL-4Ra, and low levels of
CD15 and contain high levels of arginase. Monocytic
MDSCs express the same markers but have lower levels of
CD15 and also express CD14; in addition to arginase, they
also express inducible nitric oxide synthase (iNOS). Nat-
urally occurring CD4
? Tregs are characterized by the
expression of the IL-2 receptor a-chain (CD25). These cells
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naive CD4
? CD25
? CD45RA
? T cells are exported to the
periphery [3–5]. Intracellular expression of the forkhead
box protein 3 transcription factor (FoxP3) and low
expression of the IL-7 receptor, CD127, are further char-
acteristics of suppressive Tregs [1, 6].
While there are published data on circulating Treg levels
in pancreatic cancer [7], including comprehensive clini-
copathological correlations, there is little published data
investigating MDSCs speciﬁcally in pancreatic cancer, or
indeed in esophageal and gastric cancer. Patients with
metastatic pancreatic cancer were included in an early
paper characterizing granulocytic MDSCs in cancer
patients with diverse primary tumors [8]. In another series
of over 100 patients, which included patients with pan-
creatic cancer, a signiﬁcant increase in circulating
HLADR
- Lin1
low/- CD33
? CD11b
? MDSCs was dem-
onstrated in cancer patients relative to controls: Increasing
numbers of MDSCs correlated with increasing stage of
disease and patient-derived MDSCs impaired T-cell pro-
liferation [9].
Although elevated MDSC numbers have been reported
in single tumor site series, MDSC levels, their phenotype,
and their functional effects may vary from cancer to can-
cer. We present for the ﬁrst time a comprehensive clini-
copathological correlation of circulating MDSCs and Tregs
in pancreatic, esophageal and gastric cancer patients,
together with an assessment of the functional signiﬁcance
of these changes by analysis of systemic arginase I levels.
We demonstrate that MDSC levels are an independent
prognostic factor for survival. We have evaluated the
cytokine proﬁles in these patients with particular reference
to IL-13 levels.
Materials and methods
Patients
Twenty to thirty milliliters of venous blood was collected
from pancreatic and esophago-gastric cancer patients
(N = 131) and age-/sex-matched normal healthy controls
(N = 54). Subjects were recruited between July 2008 and
April 2010. Cancer patients were recruited from oncology
clinics at St Luke’s Cancer Center, Surrey, UK, and all had
histologically conﬁrmed pancreatic or esophago-gastric
cancer. Age- and sex-matched healthy controls were
recruited from surgical minor operation clinics at the Royal
Surrey County Hospital. No subject had a history of
autoimmune disease or of recent steroid therapy, and no
control donor had a prior history of cancer. All subjects
provided written informed consent and the study was
approved by the local ethics committee. Blood was drawn
into li-heparin tubes (BD Biosciences, Europe), and fol-
lowing centrifugation, the plasma was removed and
peripheral blood mononuclear cells (PBMC) were isolated
using Ficoll-Hypaque gradients. Plasma samples were
stored at -80C, and PBMC were counted, frozen at
-80C,and storedinliquidN2 for subsequentbatch analysis.
Cancer patients were subdivided into three groups
according to the site of their primary tumor: (1) pancreatic
(N = 46), (2) esophageal, esophago-gastric junction or
cardia (primary tumor arising B5 cm below the esophago-
gastric junction) (N = 60), and (3) non-cardia gastric
cancer patients (primary tumor arising in gastric body,
fundus, or antrum) (N = 25). The following clinicopatho-
logical characteristics were recorded: age, sex, WHO per-
formance status (PS), histological grade, AJCC stage
(2010), prior weight loss, smoking status at time of sample
collection, and whether patients received subsequent sys-
temic treatment following immune testing.
Immunophenotypic analysis of cells
PBMC were recovered and washed in 0.15 M phosphate-
buffered saline, Dulbecco’s A (Oxoid, UK). Cells were
aliquoted for T-cell subset, Treg and MDSC analysis. The
LIVE/DEAD Cell Stain Kit (Invitrogen, UK) was used
to differentiate viable and dead cells. After washing in
binding buffer (BD Biosciences, Europe), the following
anti-human monoclonal antibodies were used for ﬂow
cytometry: anti-CD3-FITC, anti-CD4-PE Cy7, anti-CD8-
PE Cy5, anti-CD25-APC Cy7, anti-CD127-PE, anti-
HLADR-APC Cy7, anti-Lin1(CD3,14,16,19,20,56)-FITC,
anti-CD33-PE Cy5 and anti-CD11b-PE Cy7 (BD Biosci-
ences, Europe). For Treg intra-nuclear FoxP3 anaylsis,
permeabilization and staining for FoxP3 and an isotype
control was performed for each donor using the eBio-
science anti-FoxP3 staining set, according to the manu-
facturer’s instructions. Cells were washed in binding buffer
and analyzed using a MACSQuant ﬂow cytometer with
MACSQuantify software (Miltenyi Biotec). For T-cell
subset and Treg analysis, the acquisition and analysis gates
were restricted to the live lymphocyte population, whereas
for MDSC analysis, all live cells were included. CD3
?
CD4
? and CD3
? CD8
? cells were calculated as a per-
centage of live CD3
? lymphocytes. Tregs were identiﬁed
as CD4
? CD25
? CD127
low/- FoxP3
? and calculated as a
percentage of live CD4
? lymphocytes. Finally, HLADR
-
Lin1
low/- CD33
? CD11b
? MDSCs were calculated as a
percentage of total live PBMC.
Arginase I ELISA
Plasma arginase I levels in cancer patients (N = 119) and
controls (N = 31) were analyzed using an enzyme-linked
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type) using a commercially available kit (BioVendor, UK).
Hemolyzed samples were excluded. Samples were assayed
in duplicate and the mean absorbance was calculated from
the standard curve.
Bio-plex cytokine assay
Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13,
IL-17, G-CSF, IFN-c, TNF-a and VEGF levels in cancer
patients (N = 119) and controls (N = 33) were analyzed
using the Bio-Plex human cytokine assay (Bio-Rad, UK),
using Bio-Plex software. Hemolyzed samples were exclu-
ded and samples were assayed in duplicate.
Interleukin-13 ELISA
For validation of IL-13 levels, plasma IL-13 levels in
pancreatic cancer patients (N = 24) and controls (N = 18)
were analyzed using an enzyme-linked immunosorbent
assay speciﬁc for human IL-13 using a commercially
available kit (Thermo Scientiﬁc, UK). Hemolyzed sam-
ples were excluded. Samples were assayed in duplicate
and the mean absorbance was calculated from the stan-
dard curve.
Statistical analysis
Clinicopathological variables included age, diagnosis,
WHO performance status, tumor grade, AJCC 2010 stage,
weight loss, smoking status at time of sample collection,
prior treatment status and whether patients received any
systemic therapy following sample donation. Continuous
variables were summarized as medians and ranges. Median
levels of MDSC, Treg, arginase I and cytokines were
compared in pancreatic, esophageal and gastric cancer
patients versus controls using the nonparametric two-
sample Wilcoxon rank sum test and applying a Bonferroni
correction to control for multiple testing (statistical sig-
niﬁcance adjusted to P\0.0125). The association between
two continuous factors was investigated calculating the
Spearman’s correlation coefﬁcient.
Independent factors signiﬁcantly associated with sur-
vival were identiﬁed using log-rank (LR) analysis for cat-
egorical variables and univariate Cox proportional hazards
models for continuous variables (Wald test statistic),
including consideration of transformations for nonlinear
relationships with hazard. MDSC level was analyzed as a
continuous covariate and required no transformation. All
variables signiﬁcant at the 10% level on univariate analysis
were considered further in the multivariate setting. Multi-
variate Cox proportional hazards models were derived
using backward elimination variable selection based on a
10% level of signiﬁcance, including subsequent systemic
therapy in all models in view of its clinical relevance.
Adjusted hazard ratios for each signiﬁcant independent
factor are presented. Plots of survival estimates are pre-
sented using the method of Kaplan and Meier.
Results
Patients
We analyzed peripheral blood mononuclear cells and
cytokine proﬁles of 46 patients with pancreatic cancer, 60
with esophageal cancer, 25 with gastric cancer and 54 age-/
sex-matched controls. The patient characteristics are shown
in Table 1.
Following blood donation, the majority of patients
subsequently received systemic therapy (80.9%). Twenty-
one patients in the pancreatic cohort received standard
gemcitabine-based chemotherapy and 19 received gem-
citabine and capecitabine chemotherapy in combination
with either concomitant or sequential treatment with the
anti-telomerase class II peptide vaccine, GV1001. The 7
esophageal cancer patients who went on to receive
chemotherapy and a biological agent all received stan-
dard chemotherapy followed by treatment with an
experimental agent upon progression. The 3 esophageal
cancer patients who were subsequently treated in the
context of a randomized control trial received chemo-
therapy in combination with an EGFR monoclonal anti-
body or placebo (treatment blinded). Of the minority of
upper GI patients who had received treatment prior to
immune testing (32.1%), 11 had received neoadjuvant or
adjuvant chemotherapy prior to relapse and 31 had
received prior palliative chemotherapy. None of these
patients had received therapy within 8 weeks prior to
blood donation, and all had progressed at the time of
immune testing.
MDSCs are elevated in pancreatic, gastric
and esophageal cancer and are associated
with elevations of arginase I and Tregs
MDSC percentages were statistically signiﬁcantly elevated
in pancreatic, esophageal and gastric cancer, when com-
pared with controls (Fig. 1; Table 2), with median (range)
percentages of 2.1 (0.2–11.2): P\0.001, 1.3 (0.4–6.0):
P\0.001, 1.5 (0.2–10.0): P = 0.002, and controls 0.8
(0.1, 2.0), respectively. There was no signiﬁcant difference
in MDSC percentage in the group of patients who had
received any chemotherapy prior to immune testing and
those who had not (P = 0.61).
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achieved statistical signiﬁcance in esophageal and gastric
cancer when using a Bonferroni correction for multiple
testing. There was a strong trend toward increasing argi-
nase I level in pancreatic cancer, which did not reach sta-
tistical signiﬁcance (P = 0.020). Treg levels were also
statistically signiﬁcantly elevated in all three diseases
compared with controls (P B 0.002), and there was a
positive correlation between MDSC and Treg percentages
with a Spearman’s rank correlation of 0.43. There was no
correlation between MDSC and CD4 or CD8 percentages
(data not shown). The majority of patients in the study had
stage IV disease (64.1%) and grade 3 tumors (55.7%). As
only 44 patients (33.6%) had stage II–III disease, such
patients were combined for analysis. In our dataset, there
was no evidence of increasing MDSC percentage or of
arginase I concentration with stage (P = 0.51 and
P = 0.53, respectively). However, there was a tendency for
patients harboring high-grade tumors to have higher argi-
nase levels compared with grade 1/2 tumors (P = 0.044).
There was no signiﬁcant effect of grade on MDSC%
(P = 0.61).
Table 1 Patient characteristics
Variable Category Pancreas
N = 46
Esophagus
N = 60
Gastric
N = 25
UGI cancer
N = 131
WHO performance status 0/1 28 (60.9%) 39 (65.0%) 16 (64.0%) 83 (63.4%)
2 12 (26.1%) 16 (26.7%) 6 (24.0%) 34 (26.0%)
3 5 (10.9%) 4 (6.7%) 3 (12.0%) 12 (9.2%)
Unknown 1 (2.2%) 1 (1.7%) 0 (0.0%) 2 (1.5%)
Tumor grade 1 2 (4.3%) 1 (1.7%) 0 (0.0%) 3 (2.3%)
2 12 (26.1%) 18 (30.0%) 6 (24.0%) 36 (27.5%)
3 16 (34.8%) 40 (66.7%) 17 (68.0%) 73 (55.7%)
Not assessable
a 16 (34.8%) 1 (1.7%) 2 (8.0%) 19 (14.5%)
AJCC stage 2010 II/III 11 (23.9%) 25 (41.7%) 8 (32.0%) 44 (33.6%)
IV 33 (71.7%) 34 (56.7%) 17 (68.0%) 84 (64.1%)
Not assessable
b 2 (4.3%) 1 (1.7%) 0 (0.0%) 3 (2.3%)
Weight loss None 17 (37.0%) 21 (35.0%) 5 (20.0%) 43 (32.8%)
B10% 12 (26.1%) 20 (33.3%) 4 (16.0%) 36 (27.5%)
[10% 16 (34.8%) 17 (28.3%) 14 (56.0%) 47 (35.9%)
Unknown 1 (2.2%) 2 (3.3%) 2 (8.0%) 5 (3.8%)
Smoking status Current 7 (15.2%) 12 (20.0%) 5 (20.0%) 24 (18.3%)
Ex B 12 months 2 (4.3%) 3 (5.0%) 1 (4.0%) 6 (4.6%)
Ex[12 months 17 (37.0%) 18 (30.0%) 10 (40.0%) 45 (34.4%)
Never 15 (32.6%) 22 (36.7%) 6 (24.0%) 43 (32.8%)
Unknown 5 (10.9%) 5 (8.3%) 3 (12.0%) 13 (9.9%)
Prior treatment status None 32 (69.6%) 38 (63.3%) 19 (76.0%) 89 (67.9%)
Adjuvant/Neoadjuvant
chemotherapy
3 (6.5%) 7 (11.7%) 1 (4.0%) 11 (8.4%)
Palliative chemotherapy 11 (23.9%) 15 (25.0%) 5 (20.0%) 31 (23.7%)
Subsequent treatment status None 6 (13.0%) 13 (21.7%) 6 (24.0%) 25 (19.1%)
Chemotherapy 21 (45.7%) 28 (46.7%) 19 (76.0%) 68 (51.9%)
Chemoradiation 0 (0.0%) 8 (13.3%) 0 (0.0%) 8 (6.1%)
Biological agent 0 (0.0%) 1 (1.7%) 0 (0.0%) 1 (0.8%)
Chemotherapy and biological agent 19 (41.3%) 7 (11.7%) 0 (0.0%) 26 (19.8%)
Randomized controlled trial 0 (0.0%) 3 (5.0%) 0 (0.0%) 3 (2.3%)
Survival status Alive 9 (19.6%) 23 (38.3%) 8 (32.0%) 40 (30.5%)
Dead 37 (80.4%) 37 (61.7%) 17 (68.0%) 91 (69.5%)
Unknown 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
a Tumor grade not assessable due to insufﬁcient tissue (e.g., ﬁne-needle aspirate, cytological diagnosis)
b Stage not assessable with tumor recurrence following prior resection
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cancer shows Th2 skewing and signiﬁcant elevations
of the Th2 cytokine IL-13 (Table 3)
Table 3 shows cytokine levels for IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12, IL-13, IL-17, G-CSF, IFN-c, TNF-a and
VEGF. IL-5, IL-6 and IL10 levels were all statistically
signiﬁcantly elevated in patients’ plasma, compared with
controls (P B 0.004). We analyzed IL-13 levels by Bio-
Plex assay for all three cancers and demonstrated statisti-
cally signiﬁcant increases in IL-13 in all three diseases
compared with controls (P\0.001). We conﬁrmed the
elevated IL-13 levels in pancreatic cancer patients versus
controls using a separate ELISA (Thermo Scientiﬁc, UK)
and conﬁrmed a statistically signiﬁcant increase in IL-13
(P\0.001). As expected, there was also a highly statisti-
cally signiﬁcant elevation of VEGF in cancer patients.
There was a positive correlation between MDSC levels and
IL-13 with a Spearman’s rank correlation of 0.32.
MDSC levels are an independent prognostic factor
in pancreatic, esophageal and gastric cancer (Tables 4,
5, 6, Fig. 2)
Ninety-one (69%) of the 131 cancer patients had died at the
time of analysis. Median follow-up of the 40 alive patients
was 8.3 months (inter-quartile range: 4.1–13.5), similar
acrossdiagnosticgroups.Tables 4and5showtheunivariate
analysis of survival. As was expected, performance status
(v2
LogRank = 28.7, P\0.001), AJCC stage (v2
LogRank =
6.9, P = 0.008), and weight loss (v2
LogRank = 7.7,
P = 0.022) were statistically signiﬁcantly associated with
outcome. Median survival for patients with pancreatic can-
cer (5.0 months, 95% CI: 3.4, 7.3) was worse than that for
gastric (5.9 months, 95% CI: 4.0, 10.6) and esophageal
cancer (9.3 months, 95% CI: 7.2, 12.6). MDSC level was
signiﬁcantly associated with survival (v2
Wald = 21.3,
P\0.001), Table 5. Treg percentage, however, was not.
There was no evidence that tumor grade, smoking status,
prior or subsequent treatment status had an impact on sur-
vival in this dataset.
No control sample had an MDSC percentage of greater
than 2.0% of their total live PBMC (N = 47). Patients were
dichotomized into those with above normal range of
MDSC percentage (MDSCs[2.0%) and those with an
MDSC level in the normal range (MDSCs B 2.0%). Forty-
three patients with elevated MDSCs had an inferior sur-
vival, with a median survival of 4.6 months (95% CI: 2.2,
6.0) and 12-month survival of 10.4% compared with 80
patients with normal MDSCs, median survival of
9.3 months (95% CI: 6.3, 12.1) and 12-month survival of
39% (Fig. 2a).
A multivariable model for overall survival was based on
115 patients (82 deaths), considering all variables signiﬁ-
cant in the univariate analysis with P\0.1. The ﬁnal model
included subsequent chemotherapy and selected diagnostic
group (v2
Wald = 6.7, P = 0.036), AJCC stage (v2
Wald = 3.3,
P = 0.071), performance status (v2
Wald = 16.2, P\0.001),
and MDSC percentage (v2
Wald = 7.3, P = 0.007) as sig-
niﬁcant prognostic factors of survival (Table 6). Although
weight loss was signiﬁcant in the univariate analysis, it was
not signiﬁcant in the multivariate setting and therefore was
not included in the ﬁnal analysis. MDSC level retained
statistical signiﬁcance in the multivariable model when
adjusted by the effects of other prognostic factors. A unit
increase in MDSC percentage was associated with a 22%
increased risk of death (hazard ratio of 1.22 (95% CI:
1.06–1.41), Fig. 2b.
Discussion
The efﬁcacy of cancer vaccines and other immunotherapies
will be improved by addressing the immunosuppressive
factors associated with malignancy, both systemically and
in the local tumor microenvironment. In this comprehen-
sive analysis of some of these factors, we have shown a
statistically signiﬁcant increase in circulating MDSC
numbers in patients with pancreatic, esophageal and gastric
cancer compared with age- and sex-matched controls.
MDSCs exert their immunosuppressive activity through
multiple mechanisms, one of these being through arginine
depletion. MDSCs express high levels of arginase: Argi-
nase hydrolyzes the amino acid L-arginine to ornithine and
urea. There are two isoforms of arginase, cytoplasmic
arginase I and mitochondrial arginase II, encoded by two
different genes. MDSC expressing arginase I deplete
L-arginine from the microenvironment and profoundly
inhibit T-cell function [10, 11]. Inhibition of arginase I
restores T-cell function in vitro and induces an antitumor
response in vivo [11]. Previously, increased numbers of
MDSCs in the peripheral blood of renal cancer patients
correlated with low L-arginine and high ornithine levels in
plasma, and a profound T-cell dysfunction [12]. In this
study, we have demonstrated elevations of plasma arginase
I compared with controls in all three cancer types, and this
difference achieved levels of statistical signiﬁcance in
esophageal and gastric cancer.
MDSCs may exert their immunosuppressive effects
partially through the induction of Tregs as reported in
hepatocellular carcinoma [13]. Sunitinib caused a signiﬁ-
cant reduction in MDSC numbers in patients with renal cell
carcinoma and the change in T regulatory cells tracked
those of MDSC numbers with a signiﬁcant correlation
Cancer Immunol Immunother (2011) 60:1419–1430 1423
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Tregs in pancreatic, esophageal and gastric cancer com-
pared with controls and a positive correlation between
MDSC and Treg percentage with a Spearman’s correlation
of 0.43. These data complement previously published data
on FoxP3
? Tregs in pancreatic cancer, in which a direct
correlation between high levels of Tregs within the tumoral
lymphocytic inﬁltrate and the presence of distant metas-
tasis and high tumor stage and grade was demonstrated [7].
In a multivariate model adjusting for other clinical and
pathological variables, they found that the prevalence of
Tregs in the CD4
? T-cell population was an independent
prognostic factor. The study did not directly ascertain cir-
culating Treg numbers in the blood of these patients.
A unique and important ﬁnding of our study is that
MDSC numbers are an independent prognostic factor in
patients with pancreatic and esophago-gastric cancer. We
constructed a multivariable model in 115 patients for
overall survival including key variables of diagnosis,
performance status, stage and the use of systemic therapy
following immune assessment. MDSCs remained an inde-
pendent prognostic factor signiﬁcantly related to survival,
with a unit increase in MDSCs being associated with a 22%
increased risk of death (hazard ratio of 1.22, 95% CI
1.06–1.41). Should these ﬁndings be independently vali-
dated, MDSC percentage could become a parameter for
routine use in the prognostic modeling of these diseases.
Although we have not shown an association with MDSC
and stage (as was demonstrated in the work of Diaz-
Montero and colleagues [9]), our study speciﬁcally reports
on only 3 tumor sites. Their work included 17 different
cancers, nearly half of which were breast cancer patients. It
may be that some cancers are associated with profound
immunosuppression even at an early stage while other
cancers may only generate severe systemic immunosup-
pression when metastatic. This underlies the importance of
reporting immune status data separately for each primary
cancer type.
Bellone and colleagues ﬁrst reported an increase in
IL-10 and TGF-b concentrations in the sera of pancreatic
cancer patients and showed that the anti-proliferative
activity of pancreatic carcinoma-conditioned medium on
PBMCs was accounted for mainly by the combined action
of IL-10 and TGF-b [15]. There was an increase in IL-4
production and decrease in interferon-c and IL-12 pro-
duction from stimulated PBMCs, thus demonstrating a
skewing of T-cell cytokine production toward a Th2
immunophenotype. We conﬁrm this Th2 skewing in pan-
creatic cancer and extend these observations to esophageal
and gastric cancer, demonstrating statistically signiﬁcant
increases in the plasma concentrations of the Th2 cytokines
IL-5, IL-6 and IL-10 in these patients compared with
controls. The elevation of IL-6 is intriguing in view of
Table 2 MDSC, Treg and arginase I levels
Number patients
median (range) P value
Control
N = 54
Pancreas
N = 46
Esophagus
N = 60
Gastric
N = 25
UGI cancer
N = 125
MDSC (%) N = 47 N = 44 N = 56 N = 23 N = 123
0.8 (0.1, 2.0) 2.1 (0.2, 11.2) 1.3 (0.4, 6.0) 1.5 (0.2, 10.0) 1.4 (0.2, 11.2)
P\0.001 P\0.001 P = 0.002 P\0.001
Treg (%) N = 46 N = 40 N = 51 N = 17 N = 108
3.6 (0.6, 14.3) 7.5 (2.3, 20.6) 6.5 (1.0, 22.2) 7.8 (3.2, 20.2) 7.0 (1.0, 22.2)
P\0.001 P\0.001 P = 0.002 P\0.001
Arginase I conc. (ng/ml) N = 31 N = 44 N = 53 N = 22 N = 119
7.7 (5.0, 97.4) 16.7 (5.1, 293.0) 19.9 (5.1, 167.8) 36.5 (9.2, 195.0) 22.0 (5.1, 293.0)
P = 0.020 (ns) P\0.001 P\0.001 P\0.001
Number of patients (N), median (range), Wilcoxon rank sum test P value of cancer group versus control. The UGI (upper gastrointestinal) cancer
group consists of the pancreatic, esophageal and gastric cancer patients combined. Bonferonni correction applied due to multiple testing with the
control arm, statistical signiﬁcance adjusted to P\0.0125
Fig. 1 MDSC and Treg FACS and scatter plots of cancer patients
and healthy controls. a live HLADR
- Lin1
low/- CD33
? CD11b
?
MDSC FACS gating of PBMC of a pancreatic cancer patient (above)
and a healthy control (below). P1, the ViViD low population
represents viable cells with reduced amine staining, P2 represents
the HLADR negative, lineage low/negative population and UR3, live
HLADR
- Lin1
low/- CD33
? CD11b
? cells, calculated as a percentage
of live cells in P1. b live CD4
? CD25
? CD127
low/- FoxP3
? Treg
FACS gating of PBMC of the same pancreatic cancer patient (above)
and healthy control (below). P1, the lymphocyte population. P2,
viable lymphocytes. P4, CD4
? population. P5, CD25
? CD127
low/-.
Histograms represent the FoxP3
? Treg population (FITC
?, right) and
the FoxP3
- non-Treg population. Tregs are calculated as a percentage
of live CD4
? lymphocytes. c scatter plot of MDSC % in controls and
cancer patients. Bar denotes median in each group. *, statistically
signiﬁcant difference from healthy controls. d scatter plot of Treg %
in controls and cancer patients
b
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CSF was the most potent generator of MDSC-like sup-
pressor cells from normal donor PBMCs, compared with
all other combinations tested [16]. This adds to other
reports of IL-6 as a signiﬁcant inducer of MDSCs [17].
A particularly important ﬁnding of our study is that in
patients with pancreatic, esophageal and gastric cancer,
there is a signiﬁcant elevation of plasma IL-13. This was
initially demonstrated using the Bio-Plex assay. Other
groups have demonstrated signiﬁcant elevations of IL-13 in
Table 3 Bio-plex assay of plasma cytokines in controls and cancer patients
Number patients
median (range) P value
Control N = 33 Pancreas N = 43 Esophagus N = 52 Gastric N = 24 UGI cancer N = 119
IL-2 21.1
(0, 4434.9)
90.7
(0, 6254.2)
P = 0.38
70.6
(0, 6085.6)
P = 0.16
82.6
(0, 2543.0)
P = 0.26
81.6
(0, 6254.2)
P = 0.17
IL-4 1.2
(0, 47.4)
0
(0, 190.5)
P = 0.87
0
(0, 32.8)
P = 0.020 (ns)
8.7
(0, 123.2)
P = 0.0061
0
(0, 190.5)
P = 0.84
IL-5 0
(0, 117.0)
7.4
(0, 883.2)
P = 0.004
10.6
(0, 96.8)
P\0.001
10.2
(2.7, 242.2)
P\0.001
9.6
(0, 883.2)
P\0.001
IL-6 86.3
(8.6, 2038.3)
211.3
(30.7, 9352.1)
P\0.001
184.1
(24.7, 4606.9)
P\0.001
234.0
(13.5, 3009.3)
P = 0.0029
197.6
(13.5, 9352.1)
P\0.001
IL-10 16.8
(0, 214.5)
39.7
(0.3, 918.7)
P\0.001
38.0
(0, 668.7)
P\0.001
63.8
(5.7, 433.0)
P\0.001
42.9
(0.3, 918.7)
P\0.001
IL-12 (p70) 135.4
(0, 651.4)
149.9
(0, 12714.9)
P = 0.41
208.5
(0, 9696.6)
P = 0.074
363.3
(0, 6967.5)
P = 0.0026
201.6
(0, 12714.9)
P = 0.038 (ns)
IL-13 27.5
(0, 148.5)
112.6
(0, 2140.0)
P\0.001
74.9
(7.6, 742.6)
P\0.001
84.4
(7.6, 715.2)
P\0.001
87.0
(0, 2140.0)
P\0.001
IL-17 0
(0, 341.8)
0
(0, 143.8)
P = 0.31
0
(0, 427.3)
P = 0.56
0
(0, 460.5)
P = 0.37
0
(0, 460.5)
P = 0.36
GCSF 51.6
(0, 235.9)
52.6
(0, 328.9)
P = 0.92
19.8
(0, 249.9)
P = 0.021 (ns)
53.6
(2.6, 153.0)
P = 0.58
39.7
(0, 328.9)
P = 0.35
IFN-c
a 876.7
(0, 25060.4)
192.6
(0, 10926923.8)
P = 0.11
890.8
(0, 26288.0)
P = 0.51
1311.6
(0, 128613.3)
P = 0.25
725.8
(0, 10926923.8)
P = 0.48
TNF-a
a 29.0
(0, 1422.5)
36.7
(0, 16113.4)
P = 0.67
0
(0, 2167.3)
P = 0.046 (ns)
50.9
(0, 3730.7)
P = 0.33
27.3
(0, 16113.4)
P = 0.61
VEGF
a 798.5
(214.7, 4378.3)
1232.1
(0, 6957.3)
P = 0.068
2120.2
(160.8, 14459.6)
P\0.001
2322.7
(315.7, 11915.6)
P\0.001
1711.1
(0, 14459.6)
P\0.001
Number of patients (N), median, (Range), Wilcoxon rank sum test P value of cancer group versus control. The UGI (upper gastrointestinal)
cancer group consists of the pancreatic, esophageal and gastric cancer patients combined. Bonferonni correction applied due to multiple testing
with the control arm, statistical signiﬁcance adjusted to P\0.0125
a Logarithmic transformations applied
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123other solid tumors, for example, melanoma, using the
multiplex Luminex assay [18]. Our data contrast with that
of another more recent study by Bellone and colleagues,
who examined a large series of cytokines in patients with
pancreatic cancer [19]. They again detected elevated levels
of IL-10 and TGF-b but found that IL-13 levels were lower
in patients than in controls. We could not re-run the IL-13
assay used in their study (Euroclone ELISA) as it is no
longer commercially available, but instead used a separate
ELISA assay (Thermo Scientiﬁc) to validate our results in
the pancreatic cohort and conﬁrmed a signiﬁcant elevation
of serum IL-13 in patients relative to controls. Our data are
not the ﬁrst to contradict some of the IL-13 ﬁndings in the
Bellone study. Formentini and colleagues demonstrated the
presence of messenger RNA transcript for IL-13 in 6/6
pancreatic cancer cell lines [20]. There was detectable
IL-13 protein in the conditioned media of all of these cell
lines by ELISA. The IL-13 concentration in the MiaPaCa2
media was[300 pg/ml. In contrast, Bellone demonstrated
minimal IL-13 expression and critically a complete
absence of IL-13 in the supernatants of pancreatic cancer
cell lines using the same ELISA used to assay serum in
their study. This included cell lines also tested by
Formentini.
An elevation of IL-13 in pancreatic cancer is a biolog-
ically plausible ﬁnding. Formentini’s study demonstrated
an absence of IL-13 in normal pancreatic cells but found
high IL-13 in ductal cancer cells and evidence of IL-4R
Table 4 Univariate survival–categorical measurements
N Deaths Median S(t) (95% CI) 6-mo S(t) (%) 12-m S(t) (%) Log-rank, P value
Overall 131 91 6.9 (5.3, 9.1) 53.4 28.0 –
Diagnosis
Pancreas 46 37 5.0 (3.4, 7.3) 41.1 14.9 10.2, P = 0.006
Esophagus 60 37 9.3 (7.2, 12.6) 65.6 39.8
Gastric 25 17 5.9 (4.0, 10.6) 46.9 25.0
WHO performance status
0/1 83 51 9.1 (6.9, 10.7) 64.6 34.2 28.7, P\0.001
2 34 28 5.1 (3.9, 8.5) 41.3 20.6
3 12 11 2.4 (1.0, 4.8) 11.1 0
Tumor grade
1/2 39 25 6.9 (5.4, 12.1) 58.6 36.9 0.54, P = 0.46
3 73 54 7.2 (4.8, 9.2) 52.8 26.7
AJCC stage 2010
II/III 44 25 10.1 (6.3, 12.6) 65.0 40.6 6.9, P = 0.008
IV 84 64 5.4 (4.2, 7.3) 46.6 21.7
Weight loss
None 43 26 9.4 (6.9, 12.3) 67.8 41.1 7.7, P = 0.022
B10% 36 28 8.5 (5.3, 10.2) 61.2 25.9
[10% 47 34 4.8 (3.7, 6.9) 36.3 19.2
Smoking status
Current 24 17 5.7 (2.7, 9.3) 49.4 26.3 0.75, P = 0.69
Ex-smoker 51 35 8.1 (5.1, 11.2) 60.1 32.1
Never 43 30 7.2 (5.1, 10.1) 55.6 25.1
Prior treatment
No 89 59 6.9 (5.1, 9.2) 55.3 27.1 0.2, P = 0.68
Yes 42 32 5.4 (3.6, 9.4) 49.3 29.0
Subsequent treatment
No 25 20 5.4 (2.2, 10.1) 45.9 21.0 1.3, P = 0.25
Yes 106 71 7.2 (5.4, 9.1) 55.0 29.6
MDSC
B2.0% 80 48 9.3 (6.3, 12.1) 63.2 39.0 16.1, P\0.001
[2.0% 43 38 4.6 (2.2, 6.0) 36.6 10.4
S(t) survival
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123immunoreactivity in 40 and 43% of pancreatic cancers,
respectively, (IL-13 binds a complex of the IL-13 receptor
a1 chain (IL-13Ra1) and the IL-4 receptor a chain (IL-
4Ra)). High IL-13 was associated with lymph node
involvement and outcome, with no patient with high
expression surviving more than three years following
curative resection. They presented evidence demonstrating
that IL-13 is an autocrine growth factor in the disease. In
some pancreatic cancer cell lines, IL-13 caused a dose-
dependent increase in growth, mediated by p44/42 MAPK
signaling, which could be inhibited in a dose-dependent
manner by IL-13-neutralizing antibodies.
The ﬁnding of a positive correlation between IL-13
levels and MDSC numbers in our study lends yet more
biological plausibility to the demonstration and importance
of elevated IL-13 in these diseases, given that IL-13 also
appears to be pivotal for the full immunosuppressive
functionality of MDSCs. Tumor-induced CD11b
? spleno-
cytes can be sorted by the presence of the IL-4Ra [21]. The
IL-4Ra-positive cells are monocytoid, produce signiﬁcant
amounts of IL-13 and IFN-c, and are suppressive. The
receptor negative cells, which are polymorphonuclear-like,
do not constitutively secrete these cytokines and are non-
suppressive. The presence of the receptor is essential for
suppressor function: IL-4Ra is not subserving IL-4-medi-
ated signaling as CD11b
? cells from IL-4 knockout mice
still suppress T-cell function. Full functionality of tumor-
conditioned murine MDSCs requires the coordinated effect
of both IL-13 and IFNa, released by the cells in an auto-
crine fashion, and results in the dual expression of arginase
and nitric oxide synthase II. In cancer patients, there is a
signiﬁcant correlation between percentage IL4Ra
? CD14
?
cells and suppressive activity [22].
Highﬁll and colleagues have shown that MDSCs cul-
tured in IL-13 are signiﬁcantly more suppressive in an
allogeneic mixed leukocyte reaction than MDSCs cultured
without IL-13 [23]. This suppressive effect is directly
mediated via arginase-mediated T-cell arginine starvation.
Compared with bone marrow controls, arginase expression
was 20-fold higher in MDSCs but 350-fold higher in
MDSCs cultured in IL-13. Recent data have shown
increased arginase activity in the plasma of patients with
renal cell cancer [24]. Demonstration that this was being
released from CD14
- CD11b
? or CD66b
? MDSCs came
from the ﬁnding of lower arginase protein activity and
expression in patient MDSCs compared with autologous
polymorphonuclear cells or control granulocytes, but
higher arginase I mRNA expression in patient MDSCs.
Furthermore, there was evidence of degranulation of argi-
nase storage granules.
In conclusion, we have demonstrated a signiﬁcant
increase in circulating MDSC levels in pancreatic, esoph-
ageal and gastric cancer patients, which is correlated with
elevated Treg numbers and associated with an increased
expression of arginase I. Importantly, we developed a
multivariable model, which has demonstrated that MDSC
percentages are a strong independent prognostic factor in
these tumor types. We have conﬁrmed the Th2 cytokine
skewing previously reported in pancreatic cancer and have
extended these observations to esophageal and gastric
cancer. Critically, we have also demonstrated signiﬁcant
Fig. 2 a Overall survival for MDSC % above and within normal
limits. There was a signiﬁcant difference between cancer patients’
survival in those with a normal MDSC% (as deﬁned by the range seen
in healthy controls, B2.00%) and those with an elevated MDSC%
([2.00%): (v2
LogRank = 16.1, P\0.001). b Log (hazard) plot with
increasing MDSC %. A unit increase in MDSC percentage was
associated with an increased risk of death (hazard ratio = 1.22, 95%
CI: 1.06, 1.41)
Table 5 Univariate survival–continuous measurements
Variable N Transformation
a Wald v
2 P value
Age 131 NA 0.04 0.84
Treg (%) 108 NA 1.5 0.22
Arginase 1 119 NA 1.9 0.17
MDSC (%) 123 Linear 21.3 \0.001
NA not applicable
a Nonlinear transformations considered
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123elevations of the important Th2 cytokine IL-13. These data
not only add to our understanding of the immunobiology of
these diseases but also may be of importance in informing
studies incorporating MDSC inhibition strategies [25] and
IL-13-directed therapies [26].
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